Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Medivation, Inc.

http://www.medivation.com/

Latest From Medivation, Inc.

Lebrikizumab Among Nine Drugs To Get EMA Nod; PTC Faces Disappointment For Translarna

The European Medicines Agency has OKd nine new medicines for EU-wide approval, but recommended against renewing the conditional marketing authorization of two drugs. 

Europe Drug Review

Potential Blockbuster Lebrikizumab Among Latest Drugs Up For Decision On EU Approval

The European Medicines Agency  is set to decide whether to back EU marketing approval for eight new drugs.

Europe Drug Review

Finance Watch: Big Financings Show Investors Remain Interested In Certain Opportunities

A mix of mega-rounds and smaller seed financings show investment happening at both ends of the venture capital spectrum. In public company financings, Gilead prices $2bn note offering, Biogen secures $1.5bn for Reata deal, Inhibrx completes a $200m PIPE and the IPO market shows new signs of life.

Financing Growth

England’s NICE Turns Down Pfizer’s Talzenna In HER2-Negative Breast Cancer

Pfizer’s Talzenna is not cost effective enough to be used on the National Health Service for patients with HER2-negative advanced breast cancer with inherited BRCA mutations, according to draft guidance from England’s health technology assessment body NICE.

Europe United Kingdom
See All

Company Information

UsernamePublicRestriction

Register